DIAMOND: toripalimab & radiotherapy in nasopharyngeal carcinoma without cisplatin

0 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Jun Ma, MD, Sun Yat-sen University Cancer Center, Guangzhou, China, discusses findings from the Phase III DIAMOND trial (NCT04825952) of toripalimab with induction chemotherapy and radiotherapy, with or without concurrent cisplatin, in locoregionally advanced nasopharyngeal carcinoma (LANPC). The cisplatin-free regimen achieved non-inferior survival outcomes while significantly reducing gastrointestinal toxicity and improving patient-reported quality of life and treatment tolerability. These results support the potential for a cisplatin-sparing approach in selected patients, offering an effective and less toxic alternative in the frontline management of LANPC. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Category
Oncology
Be the first to comment

Up Next